AR060264A1 - Composicion farmaceutica que contiene lactato y calcio, usos de dicha composicion y metodo de preparacion - Google Patents

Composicion farmaceutica que contiene lactato y calcio, usos de dicha composicion y metodo de preparacion

Info

Publication number
AR060264A1
AR060264A1 ARP070101382A ARP070101382A AR060264A1 AR 060264 A1 AR060264 A1 AR 060264A1 AR P070101382 A ARP070101382 A AR P070101382A AR P070101382 A ARP070101382 A AR P070101382A AR 060264 A1 AR060264 A1 AR 060264A1
Authority
AR
Argentina
Prior art keywords
calcium
per liter
millimoles per
pharmaceutical composition
composition containing
Prior art date
Application number
ARP070101382A
Other languages
English (en)
Inventor
Xavier M Leverive
Original Assignee
Innogene Kalbiotech Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogene Kalbiotech Pte Ltd filed Critical Innogene Kalbiotech Pte Ltd
Publication of AR060264A1 publication Critical patent/AR060264A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composicion farmacéutica que contiene entre 250 y 5000 milimoles por litro de lactato o ácido láctico, entre 0,5 y 1,99 milimoles por litro de calcio y, opcionalmente, entre 2 y 10 milimoles por litro de potasio. La presente también se relaciona con usos farmacéuticos de esta composicion. Reivindicacion 32: Un método para preparar una composicion farmacéutica que contiene entre 250 y 5000 milimoles por litro de ácido láctico o lactato y entre 0,5 y 1,99 milimoles por litro de calcio, caracterizado porque dicho método comprende proveer las cantidades respectivas de ácido láctico o lactato de potasio y cloruro de calcio y disolver los compuestos en un solvente aceptable para uso farmacéutico.
ARP070101382A 2006-04-03 2007-04-03 Composicion farmaceutica que contiene lactato y calcio, usos de dicha composicion y metodo de preparacion AR060264A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SG2006/000083 WO2007114791A1 (en) 2006-04-03 2006-04-03 Lactate and calcium containing pharmaceutical composition and uses thereof

Publications (1)

Publication Number Publication Date
AR060264A1 true AR060264A1 (es) 2008-06-04

Family

ID=38563968

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101382A AR060264A1 (es) 2006-04-03 2007-04-03 Composicion farmaceutica que contiene lactato y calcio, usos de dicha composicion y metodo de preparacion

Country Status (10)

Country Link
US (1) US20090285909A1 (es)
EP (1) EP2007371A4 (es)
CN (1) CN101448491A (es)
AR (1) AR060264A1 (es)
AU (1) AU2006341414A1 (es)
BR (1) BRPI0621528A2 (es)
CA (1) CA2648598A1 (es)
MX (1) MX2008012766A (es)
TW (1) TW200808305A (es)
WO (1) WO2007114791A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9687011B2 (en) 2012-10-25 2017-06-27 Run Them Sweet Llc Blood lactate range targets and nutritional formulations and protocols to support patients
US9897609B2 (en) 2012-10-25 2018-02-20 Run Them Sweet, LLC Systems and apparatus to estimate nutritional needs of human and other patients and to support such nutritional needs
US10206422B2 (en) 2012-10-25 2019-02-19 Run Them Sweet Llc Systems and methods for monitoring of blood lactate and targeting of blood lactate via nutritional support
US9808031B2 (en) 2012-10-25 2017-11-07 Run Them Sweet Llc Systems and methods to estimate nutritional needs of human and other patients
US9232815B2 (en) 2012-10-25 2016-01-12 Run Them Sweet, LLC Blood lactate range targets and nutritional formulations and protocols to support patients
EP2912161A4 (en) * 2012-10-25 2016-08-24 Run Them Sweet Llc METHODS AND SYSTEMS FOR ESTIMATING NUTRITIONAL NEEDS OF HUMAN PATIENTS AND OTHER PATIENTS AND FOR MANAGING SUCH NUTRITIONAL NEEDS
EA202091446A1 (ru) 2018-01-12 2021-01-29 Метимеди Фармасьютикалз Ко., Лтд. Способы лечения хронических воспалительных заболеваний
CN109453113A (zh) * 2018-12-27 2019-03-12 四川太平洋药业有限责任公司 一种乳酸钠林格注射液生产工艺
EP3920846A4 (en) * 2019-02-06 2022-11-09 The Board and Trustees of the Leland Stanford Junior University BIOLOGICALLY MODIFIED VASCULAR GRAFTS FOR IMPROVED BYPASS SURGERY RESULTS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987003808A1 (en) * 1985-12-18 1987-07-02 Veech Richard L Fluid therapy with l-lactate and/or pyruvate anions
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5248507A (en) * 1991-05-31 1993-09-28 Board Of Regents, The University Of Texas System Hypertonic isochloremic formulation for circulatory shock
US6680305B1 (en) * 1993-06-04 2004-01-20 Biotime, Inc. Physiologically acceptable aqueous solutions and methods for their use
BR9406742A (pt) * 1993-06-04 1996-03-12 Biotime Inc Solução semelhante ao plasma
US6482853B1 (en) * 2000-07-12 2002-11-19 George A. Brooks Lactate thiolester for cardiac energy resuscitation and prevention of reperfusion injury and use as an energy supplement during exercise and recovery
DE10135494A1 (de) * 2001-07-20 2003-11-06 Jobst Krauskopf Verwendung eines Lactatsalzes zur Behandlung und Prophylaxe der Athereosklerose
NZ543201A (en) * 2003-05-01 2007-05-31 Innogene Kalbiotech Pte Ltd Lactate containing pharmaceutical composition and uses thereof

Also Published As

Publication number Publication date
CN101448491A (zh) 2009-06-03
TW200808305A (en) 2008-02-16
CA2648598A1 (en) 2007-10-11
AU2006341414A1 (en) 2007-10-11
WO2007114791A1 (en) 2007-10-11
EP2007371A1 (en) 2008-12-31
US20090285909A1 (en) 2009-11-19
BRPI0621528A2 (pt) 2011-12-13
MX2008012766A (es) 2009-01-22
EP2007371A4 (en) 2009-07-22

Similar Documents

Publication Publication Date Title
AR060264A1 (es) Composicion farmaceutica que contiene lactato y calcio, usos de dicha composicion y metodo de preparacion
GT200600346A (es) Nueva fórmula cristalina v de la agomelatina, un proceso para su preparación y composiciones farmacéuticas que la contienen
AR109263A2 (es) Composición que comprende moxidectina
CO6290622A2 (es) Composiciones de activo antitranspirante con un cromatograma sec que presenta una elevada intensidad de pico 4 sec para reducir la transpiración
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
AR084285A1 (es) Composiciones inmunogenicas
CL2009001766A1 (es) Composicion farmaceutica solida para administracion oral que comprende: un taxano sustancialmente amorfo definido, un portador hidrofilico definido y un tensoactivo definido; metodo para preparar la composicion; y su uso para tratar una enfermedad neoplasica.
PA8660601A1 (es) Pirazolopiridinas y sales de las mismas, una composicion farmaceutica que comprende dichos compuestos, un metodo para prepararlos y su uso
CL2008003284A1 (es) Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras.
AR056055A1 (es) Complejos cristalinos e hidratos de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno
ECSP078030A (es) Formas cristalinas y otras formas de las sales de ácido láctico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin -1-il)-1h-bencimidazol-2 -il]-1h-quinolin-2-ona
GT200500257AA (es) Procedimiento para producir derivados de amina opticamente activos
AR052238A1 (es) Formulacion de tabletas estables
CL2008000661A1 (es) Composiciones de sales bajas en sodio, metodos de preparacion, y uso de las mismas.
ECSP099563A (es) Composiciones lubricantes personales complementarias
CO6440528A2 (es) Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico.
ATE485261T1 (de) Salicylsäurederivate
CO6290629A2 (es) Composiciones de limpieza de amino ácido básico y métodos
CL2010000829A1 (es) Metodo para tratar plantas que comprende aplicar a las plantas una composicion liquida que contiene ente 0,3 a 300 miligramos de uno o mas ciclopropenos por litro de dicha composicion.
AR072685A1 (es) Composicion topica para el tratamiento de queratosis actinica
AR074283A1 (es) Composicion de champu concentrada.
CL2011000147A1 (es) Compuestos derivados de carbamato de alquiltiazol, inhibidores de la enzima faah; composicion farmaceutica que los comprende; procedimiento de preparacion de estos; y sus usos en el tratamiento de dolores agudos o cronicos, vertigo, vomitos, nauseas, epilepsias, entre otras.
PE20130377A1 (es) Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion
CL2004000899A1 (es) Composicion farmaceutica que contiene la sal sodica de telmisartan y un agente diuretico y procedimiento de preparacion.
ECSP11011001A (es) Composición farmacéutica sólida

Legal Events

Date Code Title Description
FA Abandonment or withdrawal